Art. -Nr.: HY-112440

HZX-02-059

(Synonyms: Methuosis inducer 1)

Kundenbewertung

Based on 1 Customer Validation

HZX-02-059 is an allosteric inhibitor of PIKFYVE, and a methuosis inducer. HZX-02-059 disrupts the PIKfyve/TFEB axis, suppresses tubulin polymerization, reduces phosphorylated mTOR levels, downregulates p53, PI3K/AKT, c-Myc, and NF-κB pathways. HZX-02-059 induces G₂/M cell cycle arrest, apoptosis, and inhibits cancer cell proliferation. HZX-02-059 can be used for the research of lymphoma, double-hit lymphoma, and B-cell acute lymphoblastic leukemia.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.40%
CAS. Nr.: 2240205-30-3
Formel: C₂₇H₂₀F₃N₅O
Molecular Weight:487.48

Speicherung:

Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month

HZX-02-059 Chemical Structure

CAS. Nr.: 2240205-30-3

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

Methuosis^[1]

Alle NF-κB Isoform-spezifische Produkte anzeigen :

Alle PI3K Isoform-spezifische Produkte anzeigen :

Alle Akt Isoform-spezifische Produkte anzeigen :

Alle mTOR Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
A-375	IC₅₀	0.326 μM Compound: 13	Antiproliferative activity against human A375 cells after 48 hrs by MTS assay Antiproliferative activity against human A375 cells after 48 hrs by MTS assay	[PMID: 29878764]
A549	IC₅₀	1.892 μM Compound: 13	Antiproliferative activity against human A549 cells after 48 hrs by MTS assay Antiproliferative activity against human A549 cells after 48 hrs by MTS assay	[PMID: 29878764]
BGC-823	IC₅₀	1.566 μM Compound: 13	Antiproliferative activity against human BGC823 cells after 48 hrs by MTS assay Antiproliferative activity against human BGC823 cells after 48 hrs by MTS assay	[PMID: 29878764]
HCT-116	IC₅₀	1.008 μM Compound: 13	Antiproliferative activity against human HCT116 cells after 48 hrs by MTS assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTS assay	[PMID: 29878764]
HeLa	IC₅₀	1 μM Compound: D-13	Antiproliferative activity against human HeLa cells assessed as inhibition of cell viability incubated for 24 hrs by CCK8 assay Antiproliferative activity against human HeLa cells assessed as inhibition of cell viability incubated for 24 hrs by CCK8 assay	[PMID: 38117948]
HepG2	IC₅₀	1.197 μM Compound: 13	Antiproliferative activity against human HepG2 cells after 48 hrs by MTS assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTS assay	[PMID: 29878764]
MCF-10A	IC₅₀	>10 μM Compound: 13	Cytotoxicity against human MCF10A cells assessed as reduction in cell viability after 48 hrs by MTS assay Cytotoxicity against human MCF10A cells assessed as reduction in cell viability after 48 hrs by MTS assay	[PMID: 29878764]
MCF7	IC₅₀	2.611 μM Compound: 13	Antiproliferative activity against human MCF7 cells after 48 hrs by MTS assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTS assay	[PMID: 29878764]
MDA-MB-231	IC₅₀	0.78 μM Compound: D-13	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell viability incubated for 24 hrs by CCK8 assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell viability incubated for 24 hrs by CCK8 assay	[PMID: 38117948]
MDA-MB-231	IC₅₀	1.571 μM Compound: 13	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTS assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTS assay	[PMID: 29878764]
MDA-MB-435S	IC₅₀	2.268 μM Compound: 13	Antiproliferative activity against human MDA-MB-435S cells after 48 hrs by MTS assay Antiproliferative activity against human MDA-MB-435S cells after 48 hrs by MTS assay	[PMID: 29878764]
SK-MEL-28	IC₅₀	1.37 μM Compound: 13	Antiproliferative activity against human SK-MEL-28 cells after 48 hrs by MTS assay Antiproliferative activity against human SK-MEL-28 cells after 48 hrs by MTS assay	[PMID: 29878764]
SK-MEL-30	IC₅₀	1.662 μM Compound: 13	Antiproliferative activity against human SK-MEL-30 cells after 48 hrs by MTS assay Antiproliferative activity against human SK-MEL-30 cells after 48 hrs by MTS assay	[PMID: 29878764]

In Vitro

HZX-02-059 (1 µM) binds potently to PIKFYVE (K_d = 10 nM) and strongly inhibits PIKFYVE and seven additional kinases by 99%, while inhibiting PIP4K2C by 60%^[1].
HZX-02-059 reduces the viability of lymphoma cell lines in vitro with a median IC₅₀ of 0.19 µM^[1].
HZX-02-059 (1 μM) binds potently to purified PIKfyve kinase with a K_d of 10 nM^[2].
HZX-02-059 (100 μM) inhibits purified tubulin polymerization^[2].
HZX-02-059 (2 μM; 8 h) inhibits PIKfyve activity in 293T cells, reducing PI(3,5)P₂ levels and altering late endosome/lysosome localization^[2].
HZX-02-059 (48-72 h) potently inhibits proliferation of Will-2, LR, and TMD8 DHL cell lines in a dose- and time-dependent manner, with IC₅₀ values ranging from 107 nM (Will-2, 72 h) to 344 nM (TMD8, 48 h)^[2].
HZX-02-059 (0.25-4 μM; 24-72 h) induces caspase-independent cell death in Will-2, LR, and TMD8 DHL cell lines in a dose- and time-dependent manner, primarily via late apoptotic-like cell death^[2].
HZX-02-059 (10 nM-2 μM; 6 h-5 days) triggers methuosis in Will-2 DHL cells via inhibition of the PIKfyve/TFEB axis, inducing characteristic vacuolation, reducing TFEB expression, and disrupting autophagy^[2].
HZX-02-059 (0.25-1 μM; 24 h) induces G₂/M phase cell cycle arrest in Will-2, LR, and TMD8 DHL cell lines, via inhibition of tubulin and suppression of the mTOR/Myc axis^[2].
HZX-02-059 (0-4 μM; 72 h) does not induce apoptosis in primary PBMCs from healthy donors, indicating low toxicity toward normal hematopoietic cells^[2].
HZX-02-059 (48-72 h) potently inhibits proliferation of Nalm6 and Sup-B15 B-ALL cells with IC₅₀ values ranging from 376.3 nmol/L to 1068.0 nmol/L, showing greater potency with longer 72 h incubation compared to 48 h incubation^[3].
HZX-02-059 (1 μmol/L; 12-24 h) induces prominent cytoplasmic vacuolization in Nalm6 and Sup-B15 B-ALL cells^[3].
HZX-02-059 (0.5-1.5 μmol/L; 24-48 h) induces dose- and time-dependent late apoptosis in Nalm6 and Sup-B15 B-ALL cells^[3].
HZX-02-059 (1 μmol/L; 24 h) alters transcriptome profiles in Nalm6 B-ALL cells, downregulating p53 and NF-κB pathways and upregulating apoptosis and cell cycle-related pathways^[3].
HZX-02-059 (0.5-1.5 μmol/L; 24 h) downregulates p53 signaling, PI3K/AKT signaling, and downstream c-Myc and NF-κB pathways in Nalm6 and Sup-B15 B-ALL cells, with concurrent changes in cell cycle-related protein expression^[3].
HZX-02-059 induces methuosis, inhibits proliferation, blocks cell cycle at G₂/M phase, and dysregulates the PI3K/AKT axis in B-cell acute lymphoblastic leukemia cell lines^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis^[2]

Cell Line:

Will-2, LR, and TMD8 DHL cell lines
Concentration:

0.25; 0.5; 1; 2; 4 μM
Incubation Time:

24; 48; 72 h
Result:

Induced a significant dose-dependent increase in dead (Annexin V+) cells, predominantly late apoptotic (Annexin V+/PI+) cells, and a corresponding decrease in live (Annexin V−/PI−) cells across all three DHL cell lines.

Cell Cycle Analysis^[2]

Cell Line:

Will-2, LR, and TMD8 DHL cell lines
Concentration:

0.5 μM
Incubation Time:

24 h
Result:

Caused a significant decrease in the percentage of cells in the S and G0/G1 phases, and a marked increase in the G2/M phase across all three DHL cell lines at 0.5 μM for 24 h.

Western Blot Analysis^[2]

Cell Line:

Will-2, LR, and TMD8 DHL cell lines
Concentration:

0.25; 0.5; 1 μM
Incubation Time:

24 h
Result:

Showed reduced α-tubulin, β-tubulin, phosphorylated mTOR, phosphorylated 4EBP1, and c-MYC expression, along with altered Cyclin B1 and CDC2 levels via western blot analysis, consistent with tubulin inhibition and mTOR/Myc axis suppression.

Apoptosis Analysis^[3]

Cell Line:

human B-cell acute lymphoblastic leukemia (B-ALL) cell lines Nalm6 and Sup-B15
Concentration:

0.5; 1; 1.5 μmol/L
Incubation Time:

24; 48 h
Result:

Triggered comparable levels of apoptosis in both cell lines after 24 h treatment with 1 or 1.5 μmol/L.
Induced substantial apoptosis in both cell lines after 48 h treatment with all tested concentrations.
Increased late apoptosis robustly, with no prominent increase in early apoptosis.

Western Blot Analysis^[3]

Cell Line:

human B-cell acute lymphoblastic leukemia (B-ALL) cell lines Nalm6 and Sup-B15
Concentration:

0.5; 1; 1.5 μmol/L
Incubation Time:

24 h
Result:

Decreased TP53, p27, CDC2, PI3K, phosphorylated AKT, c-Myc, and phosphorylated NF-κB p65 expression in a dose-dependent manner.
Increased cyclin B1 expression.
Decreased phosphorylated CDK2 expression.
Left cyclin D1, cyclin B2, and total CDK2 expression unchanged.

In Vivo

HZX-02-059 (20 mg/kg; i.p.; daily; 7 days) significantly inhibits double-hit lymphoma xenograft growth in mice with no significant systemic toxicity^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

NOD-Prkdc^−/−IL2rg^−/− (NPI) mice (female, 6 weeks old, double-hit lymphoma model via luciferase-labeled LR cells injection after 1 Gy irradiation)^[2]
Dosage:

20 mg/kg
Administration:

i.p.; daily; 7 consecutive days
Result:

Significantly inhibited tumor growth at day 12 compared to the vehicle group.
Showed no statistically significant difference in average body mass compared to the vehicle group.

Chemical Information

CAS. Nr. 2240205-30-3
Appearance Solid
Molecular Weight 487.48
Formel C₂₇H₂₀F₃N₅O
Color White to off-white
SMILES

CC(C=CC(NC(C1=CC(C(F)(F)F)=CC=C1)=O)=C2)=C2NC3=CC(C4=CN=CC=C4)=NC5=C3C=CN5
Synonyms

Methuosis inducer 1
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 25 mg/mL (51.28 mM; ultrasonic and warming and adjust pH to 3 with HCl and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.0514 mL

10.2568 mL

20.5137 mL

5 mM

0.4103 mL

2.0514 mL

4.1027 mL

10 mM

0.2051 mL

1.0257 mL

2.0514 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.5 mg/mL (5.13 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 2

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.17 mg/mL (4.45 mM); Clear solution

This protocol yields a clear solution of ≥ 2.17 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (21.7 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (4.27 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (286 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Roy A, et al. Selective Termination of Autophagy-Dependent Cancers. Cells. 2024 Jun 25;13(13):1096. [Content Brief]

[2]. Feng L, et al. Pharmacological targeting PIKfyve and tubulin as an effective treatment strategy for double-hit lymphoma. Cell Death Discov. 2022 Jan 28;8(1):39. [Content Brief]

[3]. Lu Z, et al. Novel PIKfyve/Tubulin Dual-target Inhibitor as a Promising Therapeutic Strategy for B-cell Acute Lymphoblastic Leukemia. Curr Med Sci. 2024 Apr;44(2):298-308. [Content Brief]

[4]. Zhen Lu, et al. An Azaindole-Based Small Molecule Hzx-02-059 Induces Methuosis in B-Cell Acute Lymphoblastic Leukemia through the PI3K/AKT Axis. Blood (2020) 136 (Supplement 1): 9.

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.0514 mL	10.2568 mL	20.5137 mL	51.2842 mL
	5 mM	0.4103 mL	2.0514 mL	4.1027 mL	10.2568 mL
	10 mM	0.2051 mL	1.0257 mL	2.0514 mL	5.1284 mL
	15 mM	0.1368 mL	0.6838 mL	1.3676 mL	3.4189 mL
	20 mM	0.1026 mL	0.5128 mL	1.0257 mL	2.5642 mL
	25 mM	0.0821 mL	0.4103 mL	0.8205 mL	2.0514 mL
	30 mM	0.0684 mL	0.3419 mL	0.6838 mL	1.7095 mL
	40 mM	0.0513 mL	0.2564 mL	0.5128 mL	1.2821 mL
	50 mM	0.0410 mL	0.2051 mL	0.4103 mL	1.0257 mL

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

HZX-02-059

MCE Bioactive Compound Library

Alle NF-κB Isoform-spezifische Produkte anzeigen

Alle PI3K Isoform-spezifische Produkte anzeigen

Alle Akt Isoform-spezifische Produkte anzeigen

Alle mTOR Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

HZX-02-059 Related Classifications

HY-112440 Related Classifications